期刊文献+

舒血宁联合贝那普利治疗2型糖尿病合并高血压肾损害的临床疗效观察 被引量:3

Effect of Shuxuening Injections Combined with Beinazepril on Type 2 Diabetes with Hypertensive Renal Damage
下载PDF
导出
摘要 目的探讨舒血宁联合贝那普利治疗2型糖尿病合并高血压肾功能损害的临床疗效。方法对2012-2013年院内确诊的2型糖尿病合并高血压并有微量白蛋白尿的180例患者随机分为2组,2组均给予常规降糖治疗,对照组给予贝那普利治疗,治疗组采用舒血宁注射液联合贝那普利治疗,观察2组患者治疗前后血压和肾功能的变化。结果观察组有效率为88.89%,对照组为67.78%,差异具有统计学意义(χ^2=11.82,P〈0.05);治疗后观察组SBP、DBP、脉压、肌酐、尿微量白蛋白(m Alb)、24 h尿蛋白等指标显著下降,与治疗前比差异具有统计学意义(P〈0.05);观察组肌酐、尿微量白蛋白(m Alb)、24 h尿蛋白与对照组治疗后相比较,差异具有统计学意义(P〈0.05)。结论舒血宁联合贝那普利能有效改善2型糖尿病合并高血压患者的早期肾损害,延缓病情进展。 OBJECTIVE To study the clinical effect of Shuxuening injections combined with beinazepril on patients with type 2diabetes and hypertensive renal damage. METHODS A total of 180 patients were randomly divided into the treatment[U3]group and the control group,all patients were diagnose with type 2 diabetes between 2012 to 2013. Conventional treatment was given to all patients in the 2 groups. Patients in the control group were treated with beinazepril,and patients in the treatment group were treated with beinazepril combined with Shuxuening injections. After the treatment,the blood pressure and renal function changes in all patients were observed. RESULTS The effective of patients in the treatment group was 88. 89%,and that of the control group was 67. 78%; the difference was statistically significant( χ^2= 11. 82,P〈0.05). After treatment,the indicators of SBP,DBP,PP,creatinine,m Alb,24 h urinary protein of patients in the treatment group were lower than before( P〈0.05). In patients of the control group,the creatinine,m Alb,24 h urinary protein were lower than before( P〈0.05). CONCLUSION Combination of Shuxuening injections and beinazepril is more effective in improving early renal damage in patients with type 2 diabetes than beinazepril alone.
出处 《今日药学》 CAS 2015年第3期212-213,217,共3页 Pharmacy Today
关键词 舒血宁 贝那普利 糖尿病合并高血压 肾功能 Shuxuening injections Beinazepril diabetes with hypertension renal function
  • 相关文献

参考文献8

二级参考文献69

  • 1翁建平.糖尿病肾病的诊断与治疗[J].临床内科杂志,2005,22(3):150-153. 被引量:79
  • 2KDOKI.KDOQI Clinical Prac'tice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease[J].Am J Kidney Dis,2007,49 (Suppl 2):S12-154.
  • 3Rodbard HW,Blonde L,Braithwaite SS,et al.American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus[J].Endocr Pract,2007,13(Suppl 1):1 -68.
  • 4Mancia G,De Backer G,Dominiczak A,et al.2007 Guidelines for the management of arterial hypertension:The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)[J].Eur Heart J,2007,28 (12):1462-1536.
  • 5Rodby RA,Rohde RD,Clarke WR,et al.The Irbesartan type Ⅱ diabetic nephropathy trial:study design and baseline patient charactoristics.For the Collaborative Study Group[J].Nephrol Dial Transplant,2000,15:487-497.
  • 6Brenner BM,Cooper ME,de Zeenw D,et al.Effects of Inesrtan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy[J].N Engl J Med,20010345:861-869.
  • 7Viberti G,Whecldon NM.Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus:a blood pressure-independent effect[J].Circulation,2002,106:672-678.
  • 8Rossing K,Christensen PK,Andersen S,et al.Comparative effects of lrbosartan on ambulatory and office blood pressure:a substudy of ambulatory blood pressure from the lrbesartan in Patients with Type 2 Diabetes and Micreslbuminuria study[J].Diabetes Care,2003,26:569-574.
  • 9Diercks GF,Janssen WM,van Boven AJ,et al.Rationale,design,and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive,nonhypercholesterolemic subjects with microalbuminuria(the Prevention of REnal and Vascular ENdstage Disease Intervention Trial[PREVEND IT])[J].Am J Cardiol,2000,86:635-638.
  • 10Ansquer JC,Fouchor C,Rattier S,et al.Fenofibrate reduces progresaion to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes:results from the Diabetes Atherosclerosis Intervention Study (DAIS).[J] Am J Kidney Dis,2005,45:485-493.

共引文献185

同被引文献28

引证文献3

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部